Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation
Reem Qannita(University of Sharjah), Yasser Bustanji(University of Jordan), Mohammad Hudaib(University of Jordan), Jalal Taneera(University of Sharjah), Shereen M. Aleidi(University of Jordan), Amani A. Harb(Al-Ahliyya Amman University), Mohamed A. Saleh, Waseem El‐Huneidi(University of Sharjah), Karem H. Alzoubi(Jordan University of Science and Technology), Mohammad H. Semreen(University of Sharjah), Ayah Alalami(University of Sharjah), Eman Abu‐Gharbieh(University of Sharjah)
Cited by 101
Related Papers
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.1k
Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study
|The Lancet Global Health|2020|1.3k
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
|The Lancet Haematology|2023|658
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet. Gastroenterology & hepatology|2020|643